RhumbLine Advisers
SLN

RhumbLine Advisers’s Silence Therapeutics SLN Stock Holding History

RhumbLine Advisers’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.4K Buy
13,935
+936
+7% +$5.15K ﹤0.01% 3513
2025
Q4 		$79K Buy
12,999
+7,134
+122% +$45.7K ﹤0.01% 3545
2025
Q3 		$30.4K Sell
5,865
-331
-5% -$1.84K ﹤0.01% 3728
2025
Q2 		$35.9K Buy
6,196
+4,321
+230% +$18.5K ﹤0.01% 3723
2025
Q1 		$5.28K Buy
1,875
+1,034
+123% +$5.05K ﹤0.01% 3897
2024
Q4 		$5.78K Buy
841
+87
+12% +$1.12K ﹤0.01% 3935
2024
Q3 		$13.7K Buy
754
+285
+61% +$5.3K ﹤0.01% 3853
2024
Q2 		$8.91K Buy
469
+454
+3,027% +$9.65K ﹤0.01% 3998
2024
Q1 		$324 Buy
15
+10
+200% +$217 ﹤0.01% 4200
2023
Q4 		$86 Hold
5
– – ﹤0.01% 4251
2023
Q3 		$49 Buy
+5
New +$37 ﹤0.01% 4290

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

RhumbLine Advisers's SLN Position: Q1 2026 in Review

RhumbLine Advisers increased its Silence Therapeutics (SLN) stake by 7.2% in Q1 2026, buying an estimated $5.15K and bringing the position to 13,935 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

RhumbLine Advisers first reported a position in SLN in Q3 2023 and has held it in 11 quarters since. The position peaked at $79K in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • RhumbLine Advisers held 13,935 shares of Silence Therapeutics worth $73.4K as of Q1 2026.
  • RhumbLine Advisers bought 936 Silence Therapeutics shares in Q1 2026, an estimated $5.15K.
  • Silence Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3513 holding.
  • RhumbLine Advisers first reported a position in Silence Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • RhumbLine Advisers's Silence Therapeutics position peaked at $79K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.